Mon, Sep 15, 2014, 9:14 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Federal National Mortgage Association Message Board

meltdownman1 12 posts  |  Last Activity: Jun 27, 2014 4:04 PM Member since: Aug 12, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • meltdownman1 meltdownman1 Jun 27, 2014 4:04 PM Flag

    Did your parents have any children who lived?

    Sentiment: Strong Buy

  • Reply to

    Turns Out Adam Feuerstein Was Right On This One

    by ijerryhale Jun 27, 2014 2:49 PM
    meltdownman1 meltdownman1 Jun 27, 2014 3:53 PM Flag

    You are depriving a village of an idiot.

    Sentiment: Strong Buy

  • Drugmaker Bristol-Myers Squibb Co. (BMY: Quote) Tuesday said a late-stage study of Nivolumab was stopped early as it demonstrated superior overall survival in certain melanoma patients compared to dacarbazine.

    In the randomized blinded comparative Phase 3 study evaluating nivolumab with dacarbazine or DTIC in patients with previously untreated BRAF wild-type advanced melanoma, an analysis conducted by the independent Data Monitoring Committee or DMC showed evidence of superior overall survival in patients receiving nivolumab compared to the control arm.

    The study, referred to as CheckMate -066, enrolled 418 patients who were randomized to receive either nivolumab 3 mg/kg every two weeks or DTIC 1000 mg/m2 every three weeks. The primary endpoint was overall survival. Secondary endpoints included progression free survival and objective response rate.

    Patients in the trial will be unblinded and allowed to cross over to nivolumab. The company will share these data with health authorities.

    Michael Giordano, MD, Head of Oncology Development, said, "The outcome of CheckMate -066 is an important milestone in the field of immuno-oncology as it represents the first well-controlled, randomized Phase 3 trial of an investigational PD-1 checkpoint inhibitor to demonstrate an overall survival benefit."

    Sentiment: Strong Buy

  • Of the people involved in the decision making process in order to get to the truth in this whole matter. The Plaintiffs are looking to catch someone in an out right lie with documents in hand to prove it. That is their strategy. The Defendent's lawyers don't want any of their people to testify...period. And we all know why now.

    Sentiment: Strong Buy

  • Reply to

    CYTR HAS NO REVENUES AND MASSIVE MARKET CAP

    by osprey.watch3 Jun 17, 2014 9:29 PM
    meltdownman1 meltdownman1 Jun 17, 2014 10:25 PM Flag

    Stick with Treasury Bills there Osprey...I am sure you will sleep better at night not having to worry about covering your short. This stock is slowly being accumulated there mate. Wake up and smell the coffee.

    Sentiment: Strong Buy

  • meltdownman1 by meltdownman1 Jun 17, 2014 11:41 AM Flag

    You playing Gale?

    Sentiment: Strong Buy

  • Reply to

    This has got to be the boringest day...

    by nealde123 Jun 16, 2014 10:41 AM
    meltdownman1 meltdownman1 Jun 16, 2014 6:17 PM Flag

    But not so much for the patients eh?

    Sentiment: Strong Buy

  • They are a leader in manufacturing Doxy...they will be pleased with the results of Aldo working with their Doxy.

    Sentiment: Strong Buy

  • So sorry but you should not have set them so tight

    Sentiment: Strong Buy

  • Reply to

    Results

    by meltdownman1 Jun 16, 2014 9:14 AM
    meltdownman1 meltdownman1 Jun 16, 2014 9:33 AM Flag

    Safety

    Adverse events were consistent with known doxorubicin toxicities. The majority of adverse events resolved prior to the following cycle with no treatment discontinuation. Aldoxorubicin-treated subjects experienced a higher percentage of Grade 3 or 4 treatment emergent adverse events (TEAEs) of neutropenia (40% vs. 20%), mucositis (11% vs. 3%) and nausea/vomiting (7% vs. 0%). All TEAEs resolved and were not treatment limiting. No clinically significant cardiac toxicity was seen with aldoxorubicin while approximately 10% of doxorubicin patients had clinically significant cardiotoxicity. Most importantly, there was no clinically significant reduction in cardiac function in the aldoxorubicin patients despite receiving 3.5 times the standard dose of doxorubicin.

    Sentiment: Strong Buy

  • Reply to

    Results

    by meltdownman1 Jun 16, 2014 9:14 AM
    meltdownman1 meltdownman1 Jun 16, 2014 9:29 AM Flag

    Updated median PFS at 6 months results are described here:

    All Subjects P Value
    Scans Read by Investigator
    Aldoxorubicin 68.1% P=0.002
    Doxorubicin 36.6%
    Improvement over dox 86.1%
    Scans Read by Blinded Central Lab
    Aldoxorubicin 45.7% P=0.02
    Doxorubicin 22.9%
    Improvement over dox 99.6%


    Updated ORR results are described in the table below. Responses were evaluated using the RECIST 1.1 criteria. Partial responses are defined as at least 30% shrinkage in the target tumors with no increase in non-target tumors or development of new tumors. Complete responses are defined as disappearance of all target lesions.

    Aldoxorubicin Doxorubicin
    Scans Read by Investigator
    Complete response 2.4% 0.0%
    Partial response 19.3% 5.0%
    ORR 21.7% 5.0%
    Scans Read by Blinded Central Lab
    Complete response 0.0% 0.0%
    Partial response 23.8% 0.0%
    ORR 23.8% 0.0%


    The percentage of patients having some shrinkage of their tumors as assessed by RECIST 1.1 criteria is shown below. Regardless of whether the scans were evaluated by investigators or by blinded reviewers, a higher percentage of patients who received aldoxorubicin treatment demonstrated tumor shrinkage compared with patients treated with doxorubicin.

    Aldoxorubicin Doxorubicin
    Scans Read by Investigator
    Tumor Shrinkage (% of subjects) 64.5 41.2
    Scans Read by Blinded Review
    Tumor Shrinkage (% of subjects) 60.8 39.4

  • meltdownman1 by meltdownman1 Jun 16, 2014 9:14 AM Flag

    n this 123-subject, 31-center Phase 2b trial, subjects with advanced soft tissue sarcomas were randomized 2:1 to receive either 350 mg/m2 of aldoxorubicin (83 subjects) or 75 mg/m2 of doxorubicin (40 subjects) every 3 weeks for up to 6 cycles. Subjects were then followed every 6 weeks with CT scans to monitor tumor size. Two approaches were used to evaluate the efficacy of aldoxorubicin compared to doxorubicin in patients with soft tissue sarcomas: assessment by the study investigators, as well as assessment by a blinded central laboratory review. The primary endpoint was PFS and secondary endpoints included PFS at 6 months for each group, ORR (complete and partial) and overall survival which will be reported when the clinical trial is complete.

    Efficacy

    As determined by both the trial investigators and by blinded central radiology review, subjects treated with aldoxorubicin demonstrated highly statistically significant better clinical outcomes than subjects that received standard doxorubicin therapy for their soft tissue sarcomas. Specifically, both assessments showed an unambiguous 79-104% improvement in PFS among patients treated with aldoxorubicin. Updated median PFS results are described in the table below.

    All Subjects P Value
    Scans Read by Investigator
    Aldoxorubicin 8.4 months P=0.0004
    Doxorubicin 4.7 months
    Improvement over dox 3.7 months (79%)
    Hazard ratio 0.419 (0.25 - 0.69) P=0.0007
    Scans Read by Blinded Central Lab
    Aldoxorubicin 5.7 months P=0.014
    Doxorubicin 2.8 months
    Improvement over dox 2.9 months (104%)
    Hazard ratio 0.584 (0.37 - 0.93) P=0.024

    Sentiment: Strong Buy

FNMA.OB
0.00(0.00%)

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Avanir Pharmaceuticals, Inc.
NasdaqGSMon, Sep 15, 2014 4:00 PM EDT
Netflix, Inc.
NasdaqGSMon, Sep 15, 2014 4:00 PM EDT